Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303).

Reckamp KL, Frankel PH, Ruel N, Mack PC, Gitlitz BJ, Li T, Koczywas M, Gadgeel SM, Cristea MC, Belani CP, Newman EM, Gandara DR, Lara PN Jr.

Front Oncol. 2019 Mar 11;9:132. doi: 10.3389/fonc.2019.00132. eCollection 2019.

2.

A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors.

Liu SV, Groshen SG, Kelly K, Reckamp KL, Belani C, Synold TW, Goldkorn A, Gitlitz BJ, Cristea MC, Gong IY, Semrad TJ, Xu Y, Xu T, Koczywas M, Gandara DR, Newman EM.

Cancer Chemother Pharmacol. 2018 Oct;82(4):723-732. doi: 10.1007/s00280-018-3672-y. Epub 2018 Aug 20.

PMID:
30128950
3.

Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.

Ferris RL, Saba NF, Gitlitz BJ, Haddad R, Sukari A, Neupane P, Morris JC, Misiukiewicz K, Bauman JE, Fenton M, Jimeno A, Adkins DR, Schneider CJ, Sacco AG, Shirai K, Bowles DW, Gibson M, Nwizu T, Gottardo R, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM, Cohen EEW.

JAMA Oncol. 2018 Nov 1;4(11):1583-1588. doi: 10.1001/jamaoncol.2018.1888.

4.

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).

Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW, Pettinger A, Foster NR, Riess JW, Agulnik M, Chang AYC, Chopra A, Kish JA, Chung CH, Adkins DR, Cullen KJ, Gitlitz BJ, Lim DW, To KF, Chan KCA, Lo YMD, King AD, Erlichman C, Yin J, Costello BA, Chan ATC.

J Clin Oncol. 2018 May 10;36(14):1412-1418. doi: 10.1200/JCO.2017.77.0388. Epub 2018 Mar 27. Erratum in: J Clin Oncol. 2018 Aug 1;36(22):2360.

5.

Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.

Horn L, Infante JR, Reckamp KL, Blumenschein GR, Leal TA, Waqar SN, Gitlitz BJ, Sanborn RE, Whisenant JG, Du L, Neal JW, Gockerman JP, Dukart G, Harrow K, Liang C, Gibbons JJ, Holzhausen A, Lovly CM, Wakelee HA.

Clin Cancer Res. 2018 Jun 15;24(12):2771-2779. doi: 10.1158/1078-0432.CCR-17-2398. Epub 2018 Mar 21.

6.

Publisher Correction: Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs.

Vannini I, Wise PM, Challagundla KB, Plousiou M, Raffini M, Bandini E, Fanini F, Paliaga G, Crawford M, Ferracin M, Ivan C, Fabris L, Davuluri RV, Guo Z, Cortez MA, Zhang X, Chen L, Zhang S, Fernandez-Cymering C, Han L, Carloni S, Salvi S, Ling H, Murtadha M, Neviani P, Gitlitz BJ, Laird-Offringa IA, Nana-Sinkam P, Negrini M, Liang H, Amadori D, Cimmino A, Calin GA, Fabbri M.

Nat Commun. 2018 Jan 8;9(1):160. doi: 10.1038/s41467-017-02485-1.

7.

Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs.

Vannini I, Wise PM, Challagundla KB, Plousiou M, Raffini M, Bandini E, Fanini F, Paliaga G, Crawford M, Ferracin M, Ivan C, Fabris L, Davuluri RV, Guo Z, Cortez MA, Zhang X, Chen L, Zhang S, Fernandez-Cymering C, Han L, Carloni S, Salvi S, Ling H, Murtadha M, Neviani P, Gitlitz BJ, Laird-Offringa IA, Nana-Sinkam P, Negrini M, Liang H, Amadori D, Cimmino A, Calin GA, Fabbri M.

Nat Commun. 2017 Nov 27;8(1):1801. doi: 10.1038/s41467-017-01562-9. Erratum in: Nat Commun. 2018 Jan 8;9(1):160.

8.

Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?

Ou SI, Lee TK, Young L, Fernandez-Rocha MY, Pavlick D, Schrock AB, Zhu VW, Milliken J, Ali SM, Gitlitz BJ.

Lung Cancer. 2017 Apr;106:110-114. doi: 10.1016/j.lungcan.2017.02.005. Epub 2017 Feb 9.

9.

HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib.

Ou SI, Schrock AB, Bocharov EV, Klempner SJ, Haddad CK, Steinecker G, Johnson M, Gitlitz BJ, Chung J, Campregher PV, Ross JS, Stephens PJ, Miller VA, Suh JH, Ali SM, Velcheti V.

J Thorac Oncol. 2017 Mar;12(3):446-457. doi: 10.1016/j.jtho.2016.11.2224. Epub 2016 Nov 27.

10.

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.

Konduri K, Gallant JN, Chae YK, Giles FJ, Gitlitz BJ, Gowen K, Ichihara E, Owonikoko TK, Peddareddigari V, Ramalingam SS, Reddy SK, Eaby-Sandy B, VavalĂ  T, Whiteley A, Chen H, Yan Y, Sheehan JH, Meiler J, Morosini D, Ross JS, Stephens PJ, Miller VA, Ali SM, Lovly CM.

Cancer Discov. 2016 Jun;6(6):601-11. doi: 10.1158/2159-8290.CD-16-0075. Epub 2016 Apr 21.

11.

Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.

Lara PN Jr, Moon J, Redman MW, Semrad TJ, Kelly K, Allen JW, Gitlitz BJ, Mack PC, Gandara DR.

J Thorac Oncol. 2015 Jan;10(1):110-5. doi: 10.1097/JTO.0000000000000385.

12.

Eribulin: a new-generation antimicrotubule agent in lung cancer therapy.

Thara E, Gitlitz BJ.

Future Oncol. 2014 Oct;10(12):1913-24. doi: 10.2217/fon.14.155. Review.

PMID:
25386810
13.

Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors.

Piatek CI, Raja GL, Ji L, Gitlitz BJ, Dorff TB, Quinn DI, Hu J, El-Khoueiry AB, Pham HQ, Roman L, Garcia AA.

Cancer Chemother Pharmacol. 2014 Dec;74(6):1227-34. doi: 10.1007/s00280-014-2600-z. Epub 2014 Nov 6.

PMID:
25374407
14.

A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer.

Gitlitz BJ, Bernstein E, Santos ES, Otterson GA, Milne G, Syto M, Burrows F, Zaknoen S.

J Thorac Oncol. 2014 Apr;9(4):577-82. doi: 10.1097/JTO.0000000000000082.

15.

Epigenetic therapy in lung cancer.

Liu SV, Fabbri M, Gitlitz BJ, Laird-Offringa IA.

Front Oncol. 2013 May 30;3:135. doi: 10.3389/fonc.2013.00135. eCollection 2013.

16.

Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.

Campbell NP, Kunnavakkam R, Leighl N, Vincent MD, Gandara DR, Koczywas M, Gitlitz BJ, Agamah E, Thomas SP, Stadler WM, Vokes EE, Kindler HL.

Lung Cancer. 2012 Oct;78(1):76-80. doi: 10.1016/j.lungcan.2012.06.011. Epub 2012 Jul 23.

17.

A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial.

Gitlitz BJ, Tsao-Wei DD, Groshen S, Davies A, Koczywas M, Belani CP, Argiris A, Ramalingam S, Vokes EE, Edelman M, Hoffman P, Ballas MS, Liu SV, Gandara DR.

J Thorac Oncol. 2012 Mar;7(3):574-8. doi: 10.1097/JTO.0b013e31823f43ca.

18.

Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.

Daud AI, Krishnamurthi SS, Saleh MN, Gitlitz BJ, Borad MJ, Gold PJ, Chiorean EG, Springett GM, Abbas R, Agarwal S, Bardy-Bouxin N, Hsyu PH, Leip E, Turnbull K, Zacharchuk C, Messersmith WA.

Clin Cancer Res. 2012 Feb 15;18(4):1092-100. doi: 10.1158/1078-0432.CCR-11-2378. Epub 2011 Dec 16.

19.

A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study.

Chao J, Synold TW, Morgan RJ Jr, Kunos C, Longmate J, Lenz HJ, Lim D, Shibata S, Chung V, Stoller RG, Belani CP, Gandara DR, McNamara M, Gitlitz BJ, Lau DH, Ramalingam SS, Davies A, Espinoza-Delgado I, Newman EM, Yen Y.

Cancer Chemother Pharmacol. 2012 Mar;69(3):835-43. doi: 10.1007/s00280-011-1779-5. Epub 2011 Nov 22.

20.

Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.

Mileshkin L, Hicks RJ, Hughes BG, Mitchell PL, Charu V, Gitlitz BJ, Macfarlane D, Solomon B, Amler LC, Yu W, Pirzkall A, Fine BM.

Clin Cancer Res. 2011 May 15;17(10):3304-15. doi: 10.1158/1078-0432.CCR-10-2763. Epub 2011 Mar 1.

21.

Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial.

Gitlitz BJ, Moon J, Glisson BS, Reimers HJ, Bury MJ, Floyd JD, Schulz TK, Sundaram PK, Ho C, Gandara DR.

J Thorac Oncol. 2010 Nov;5(11):1835-40. doi: 10.1097/JTO.0b013e3181f0bd78.

22.

Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors.

Iqbal S, Tsao-Wei DD, Quinn DI, Gitlitz BJ, Groshen S, Aparicio A, Lenz HJ, El-Khoueiry A, Pinski J, Garcia AA.

Am J Clin Oncol. 2011 Feb;34(1):27-31. doi: 10.1097/COC.0b013e3181cae766.

PMID:
20142723
23.

Metastatic renal cell carcinoma: CT-guided immunotherapy as a technically feasible and safe approach to delivery of gene therapy for treatment.

Suh RD, Goldin JG, Wallace AB, Sheehan RE, Heinze SB, Gitlitz BJ, Figlin RA.

Radiology. 2004 May;231(2):359-64.

PMID:
15128982
24.

Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer.

Pantuck AJ, van Ophoven A, Gitlitz BJ, Tso CL, Acres B, Squiban P, Ross ME, Belldegrun AS, Figlin RA.

J Immunother. 2004 May-Jun;27(3):240-53.

PMID:
15076142
25.

Cell, gene and vaccine based strategies in kidney cancer.

Gitlitz BJ, Figlin RA.

Cancer Treat Res. 2003;116:183-98. Review. No abstract available.

PMID:
14650833
26.

A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma.

Gitlitz BJ, Baker C, Chapman Y, Allen HJ, Bosserman LD, Patel R, Sanchez JD, Shapiro RM, Figlin RA.

Cancer. 2003 Nov 1;98(9):1863-9.

27.

A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma.

Gitlitz BJ, Belldegrun AS, Zisman A, Chao DH, Pantuck AJ, Hinkel A, Mulders P, Moldawer N, Tso CL, Figlin RA.

J Immunother. 2003 Sep-Oct;26(5):412-9.

PMID:
12973030
28.

Cytokine-based therapy for metastatic renal cell cancer.

Gitlitz BJ, Figlin RA.

Urol Clin North Am. 2003 Aug;30(3):589-600. Review.

PMID:
12953757
30.

Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection.

Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J, Gitlitz BJ, Figlin RA, Belldegrun AS.

J Urol. 2003 Jun;169(6):2076-83.

PMID:
12771723
31.

Phase I trial of granulocyte macrophage-colony stimulating factor and interleukin-4 as a combined immunotherapy for patients with cancer.

Gitlitz BJ, Figlin RA, Kiertscher SM, Moldawer N, Rosen F, Roth MD.

J Immunother. 2003 Mar-Apr;26(2):171-8.

PMID:
12616109
32.

Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma.

Han KR, Pantuck AJ, Bui MH, Shvarts O, Freitas DG, Zisman A, Leibovich BC, Dorey FJ, Gitlitz BJ, Figlin RA, Belldegrun AS.

Urology. 2003 Feb;61(2):314-9.

PMID:
12597937
33.

Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy.

Zisman A, Wieder JA, Pantuck AJ, Chao DH, Dorey F, Said JW, Gitlitz BJ, deKernion JB, Figlin RA, Belldegrun AS.

J Urol. 2003 Mar;169(3):909-16.

PMID:
12576811
34.

Dendritic cell-based immunotherapy of renal cell carcinoma.

Gitlitz BJ, Figlin RA, Pantuck AJ, Belldegrun AS.

Curr Urol Rep. 2001 Feb;2(1):46-52. Review.

PMID:
12084295
35.

Mathematical model to predict individual survival for patients with renal cell carcinoma.

Zisman A, Pantuck AJ, Dorey F, Chao DH, Gitlitz BJ, Moldawer N, Lazarovici D, deKernion JB, Figlin RA, Belldegrun AS.

J Clin Oncol. 2002 Mar 1;20(5):1368-74.

PMID:
11870181
36.

Collecting duct renal cell carcinoma: clinical study of a rare tumor.

Chao D, Zisman A, Pantuck AJ, Gitlitz BJ, Freedland SJ, Said JW, Figlin RA, Belldegrun AS.

J Urol. 2002 Jan;167(1):71-4.

PMID:
11743278
37.

Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome.

Zisman A, Pantuck AJ, Chao D, Dorey F, Said JW, Gitlitz BJ, de Kernion JB, Figlin RA, Belldegrun AS.

J Urol. 2001 Jul;166(1):54-8.

PMID:
11435822
38.

Vaccine and gene therapy of renal cell carcinoma.

Gitlitz BJ, Belldegrun AS, Figlin RA.

Semin Urol Oncol. 2001 May;19(2):141-7. Review.

PMID:
11354534
39.
40.

Improved prognostication of renal cell carcinoma using an integrated staging system.

Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D, Gitlitz BJ, deKernion JB, Figlin RA, Belldegrun AS.

J Clin Oncol. 2001 Mar 15;19(6):1649-57.

PMID:
11250993
41.

Adoptive cellular therapy.

Hoffman DM, Gitlitz BJ, Belldegrun A, Figlin RA.

Semin Oncol. 2000 Apr;27(2):221-33. Review.

PMID:
10768601
42.
43.

Immunomodulatory dendritic cells generated from nonfractionated bulk peripheral blood mononuclear cell cultures induce growth of cytotoxic T cells against renal cell carcinoma.

Hinkel A, Tso CL, Gitlitz BJ, Neagos N, Schmid I, Paik SH, deKernion J, Figlin R, Belldegrun A.

J Immunother. 2000 Jan;23(1):83-93.

PMID:
10687141
44.

Immunotherapy and gene therapy.

Gitlitz BJ, Belldegrun A, Figlin RA.

Semin Urol Oncol. 1996 Nov;14(4):237-43. Review.

PMID:
8946624
45.

Immunologic approaches to the treatment of cancer.

Figlin RA, Gitlitz BJ, Belldegrun A.

Cancer Invest. 1995;13(3):339-40. No abstract available.

PMID:
7743386

Supplemental Content

Loading ...
Support Center